INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Research Article

An Analytical Study of Rare-Type Parkinsonism: A Proposed Therapeutic Approach Through a Combination of Medicines

Tanujit Mondal[1*], Arnab Maitra[2], Kausik Barik[3]

[1] *Dept. of Civil Engineering, NITTTR Kolkata,.*
[2] *M.Tech AIML, Independent Researcher.*
[3] *M.Tech Scholar, Dept. of Civil Engineering, NITTTR Kolkata.*

ARTICLE INFO

Published: 21 Nov 2026
Keywords:
Alpha-synuclein, Atypical Parkinsonism, Tarentula hispanica, VMAT2, Dopamine, Levadopa, Carbidopa, Oxidative Stress
DOI:
10.5281/zenodo.24414681

ABSTRACT

Rare or atypical forms of Parkinsonism are associated with complex neurodegenerative mechanisms, including the accumulation and aggregation of misfolded alpha-synuclein proteins. These protein aggregates may interfere with normal neuronal function and dopamine regulation. One proposed mechanism involves the downregulation of vesicular monoamine transporter 2 (VMAT2), resulting in impaired dopamine storage within synaptic vesicles and increased cytosolic dopamine accumulation. Excess cytosolic dopamine may contribute to oxidative stress, potentially accelerating neuronal damage. The present study explores a proposed therapeutic approach involving Tarentula hispanica in combination with levadopa and carbidopa. The underlying hypothesis is that Tarentula hispanica may have a role in addressing alpha-synuclein-associated pathological processes, while levadopa and carbidopa support dopamine replacement. Entacapan, a catechol-O-methyltransferase (COMT) inhibitor, is also considered as a potential component of the proposed combination. A reported patient experiencing significant tremors associated with atypical Parkinsonism was initially treated with levadopa and carbidopa. Subsequently, Tarentula hispanica 30 was introduced as an additional preparation. Improvement in tremor severity was reported following the combined treatment. This study presents a preliminary hypothesis concerning a possible therapeutic combination. However, the proposed biological mechanisms and reported clinical observations require systematic laboratory investigation and controlled clinical evaluation before any therapeutic effectiveness can be established.

***Corresponding Author:** Tanujit Mondal
Address: Dept. of Civil Engineering, NITTTR Kolkata,
Email ✉: tanujit700144@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

INTRODUCTION

Parkinsonism is a neurological condition associated with disturbances in motor functions, including tremors, rigidity and impaired movement. Rare and atypical forms of Parkinsonism may involve complex pathological mechanisms, particularly the accumulation of abnormal alpha-synuclein proteins.

Alpha-synuclein is a naturally occurring neuronal protein. Under pathological conditions, misfolded alpha-synuclein may aggregate and form toxic protein clumps. These aggregates can interfere with neuronal activities and contribute to neurodegenerative processes.

One proposed mechanism involves the disruption of dopamine storage and vesicular packaging. Vesicular monoamine transporter 2 (VMAT2) plays an important role in transporting dopamine from the neuronal cytoplasm into synaptic vesicles for storage and subsequent release.

Pathological alpha-synuclein accumulation has been associated with disturbances in vesicular trafficking and dopamine regulation. Impaired vesicular storage may result in increased cytosolic dopamine levels.

Excess dopamine in the neuronal cytoplasm can undergo oxidation, producing reactive oxygen species and contributing to oxidative stress. This oxidative stress may further damage neuronal components and potentially promote additional alpha-synuclein misfolding and aggregation.

Consequently, a potential pathological cycle may develop:

1. Alpha-synuclein misfolding and aggregation.
2. Disruption of normal vesicular dopamine storage.
3. Increased cytosolic dopamine accumulation.
4. Dopamine oxidation and oxidative stress.
5. Further neuronal damage and protein aggregation.

This study explores a proposed therapeutic combination involving Tarentula hispanica, levadopa and carbidopa, with the objective of investigating a possible approach to managing symptoms and the underlying pathological processes associated with atypical Parkinsonism.

Levadopa acts as a dopamine precursor, while carbidopa reduces the peripheral conversion of levadopa into dopamine, thereby increasing the availability of levadopa for central nervous system activity.

Entacapan, a COMT inhibitor, is also considered in the proposed therapeutic combination to reduce peripheral levadopa metabolism and potentially improve its availability.

The central hypothesis of this study is that combining conventional dopaminergic treatment with the proposed Tarentula hispanica preparation may provide a potential approach for further investigation in patients experiencing atypical Parkinsonian symptoms.

Proposed Mechanism of Action

The proposed pathological mechanism primarily focuses on the relationship between alpha-synuclein aggregation, VMAT2 dysfunction and dopamine-associated oxidative stress.

Under normal physiological conditions, VMAT2 transports dopamine into synaptic vesicles, where it remains stored until its release is required.

However, pathological alpha-synuclein aggregation may interfere with normal vesicular function and dopamine handling.

The proposed sequence is as follows:

Step 1: Alpha-synuclein aggregation

Misfolded alpha-synuclein proteins aggregate and form potentially toxic structures within neuronal cells.

Step 2: Disruption of dopamine packaging

Abnormal protein accumulation may interfere with vesicular transport mechanisms, including VMAT2-mediated dopamine storage.

Step 3: Cytosolic dopamine accumulation

When dopamine is not efficiently transported into vesicles, its concentration in the neuronal cytoplasm may increase.

Step 4: Oxidative stress

Excess cytosolic dopamine may undergo oxidation, generating reactive oxygen species and contributing to oxidative stress.

Step 5: Neurodegenerative progression

Oxidative stress may promote further neuronal injury and potentially contribute to additional protein misfolding and aggregation.

The proposed therapeutic approach aims to address this pathological process while maintaining dopamine availability through conventional medication.

MATERIALS AND METHODOLOGY

Proposed Therapeutic Components

The study considers the following therapeutic components:

A. Tarentula hispanica

Tarentula hispanica is proposed as an additional preparation in the therapeutic combination. The original hypothesis associates this preparation with hyaluronic acid, hyaluronidase-related activity and substances described as Dycotoxin I and II.

The proposed mechanism suggests that these components may influence the pathological environment associated with alpha-synuclein aggregation.

However, the presence, identity and biological activity of these substances in the specific preparation require independent scientific verification.

B. Levadopa

Levadopa is used as a dopamine precursor. It crosses the blood-brain barrier and is converted into dopamine in the central nervous system.

C. Carbidopa

Carbidopa inhibits peripheral aromatic L-amino acid decarboxylase activity, reducing the peripheral conversion of levadopa into dopamine.

D. Entacapan

Entacapan is a COMT inhibitor that reduces peripheral metabolism of levadopa and may prolong its availability.

Proposed Combination

The study describes the following proposed combinations:

a) Tarentula hispanica 1M or 30.

b) Tarentula hispanica 30 in combination with levadopa and carbidopa.

c) Tarentula hispanica 30 with levadopa, carbidopa and the COMT inhibitor Entacapan.

These combinations are presented as proposed formulations for investigation rather than established treatment protocols.

Proposed Biochemical Explanation

The original hypothesis suggests that Tarentula hispanica may influence the environment associated with alpha-synuclein aggregation.

It further proposes that the preparation may help address the pathological disturbances associated with dopamine storage and VMAT2 function.

The proposed approach therefore combines two objectives:

1. Investigating a possible effect on alpha-synuclein-associated pathological processes.
2. Supporting dopamine availability through levadopa and carbidopa.

The biochemical interactions between these components have not been established by the observations presented in this study.

RESULTS AND DISCUSSION

Reported Patient Observation

According to the case description, a patient identified as Mr. Shil was experiencing significant tremors associated with atypical Parkinsonism.

Initially, the patient was prescribed:

a) Levadopa: 100 mg.

b) Carbidopa: 25 mg.

c) Frequency: Three times daily.

The patient continued to experience considerable tremors despite the initial treatment.

After approximately one year, Tarentula hispanica 30 was introduced as an additional preparation alongside levadopa and carbidopa.

The record describes the preparation as being administered in a diluted form, with three drops in one cup of water and two teaspoons taken as recorded.

Following the introduction of the combined regimen, improvement in the patient's reported condition was noted. The patient was described as feeling better, with a reduction in the severity of tremors.

Interpretation of the Observations

The reported improvement provides the basis for considering the proposed combination as a subject for further investigation.

Levadopa and carbidopa are established components of dopaminergic treatment for Parkinsonian symptoms.

However, the observed improvement cannot independently establish an additional therapeutic effect of Tarentula hispanica.

Several factors may influence the reported clinical response, including:

a) The effects of conventional dopaminergic medication.

b) Natural fluctuations in Parkinsonian symptoms.

c) Changes in treatment response over time.

d) Individual differences in disease progression.

Furthermore, the study does not provide objective tremor measurements, standardised clinical rating scores, laboratory findings or a control group.

Therefore, the reported observation should be considered preliminary and hypothesis-generating rather than evidence of treatment efficacy.

CONCLUSION

This study explores a proposed therapeutic approach for atypical Parkinsonism based on the relationship between alpha-synuclein aggregation, VMAT2 dysfunction, dopamine accumulation and oxidative stress.

The central hypothesis suggests that impaired vesicular dopamine storage may increase cytosolic dopamine concentrations, potentially contributing to oxidative stress and neuronal damage.

A combination involving Tarentula hispanica with levadopa and carbidopa has been proposed as a possible subject for further investigation. Entacapone has also been considered as an additional component because of its role as a COMT inhibitor.

A reported patient observation describes a reduction in tremor severity following the introduction of Tarentula hispanica 30 alongside conventional dopaminergic medication.

Nevertheless, the available observation is insufficient to establish the effectiveness of the proposed combination or to demonstrate that Tarentula hispanica influences alpha-synuclein aggregation or VMAT2 activity.

Further investigations are necessary, including biochemical studies, laboratory experiments and properly designed clinical trials.

In conclusion, the proposed combination represents a preliminary research hypothesis that requires rigorous scientific validation before any therapeutic recommendation can be made.

Limitations and Future Scope

The present study has several important limitations:

1. The clinical observation is based on a single reported patient.
2. No control group or comparative treatment analysis is available.
3. Objective measurements of tremor severity and disease progression have not been provided.
4. The proposed biochemical effects of Tarentula hispanica have not been experimentally demonstrated.
5. The composition and biological activity of the specific preparation require verification.
6. No systematic safety or adverse-effect assessment has been reported.

Future research should investigate the proposed mechanism through appropriate biochemical and cellular studies, particularly focusing on alpha-synuclein aggregation, VMAT2 expression and dopamine-associated oxidative stress.

Controlled clinical research would also be required to determine whether the proposed preparation provides any additional benefit beyond established treatment.

REFERENCES

1. Pitz V.,Makarious M.B et. all. “Analysis of rare Parkinson’s disease variants in millions of people” npj Parkinson’s Disease (2024) 11.
2. Blauwendraat C.,Nalls M.A & Singleton A.B “The genetic architecture of Parkinson’s disease” Lancet Neurol. 19,170-178 (2020).
3. Papadimitriou A. et. All “Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology 52,651-654 (1999)
4. Zimprich A. et. All “Mutations in LRRK2 cause autosomal- dominant parkinsonism with pleo-morphic pathology” Neuron 44,601-607 (1998)
5. Kitada T. et. All “Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism” Nature 392, 605-6608 (1998)
6. Valente E.M. et. All “Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304, 1091-1102 (2019).

HOW TO CITE: Tanujit Mondal, Arnab Maitra, Kausik Barik, An Analytical Study of Rare-Type Parkinsonism: A Proposed Therapeutic Approach Through a Combination of Medicines, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 11, 3857-3861. https://doi.org/10.5281/zenodo.24414681